Drug intelligence / Profile preview

ARTX-425

Development stage: Preclinical
Lead developer: Artus Tx
Modality: Small Molecules
Administration: Oral

Overview

ARTX-425 is an orally administered small molecule therapeutic currently in preclinical development by Artus Therapeutics. It is designed to address gut barrier dysfunction, a condition implicated in various gastrointestinal, neurological, and metabolic disorders. The drug's mechanism of action focuses on enhancing the integrity of epithelial and endothelial barriers to facilitate mucosal healing. Unlike many conventional treatments for inflammatory conditions, ARTX-425 aims to restore barrier function without compromising the patient's immune system, potentially offering a safer long-term therapeutic profile for chronic barrier-related diseases.

Targets

AHR (Aryl hydrocarbon receptor)

Beyond the preview

Go deeper on ARTX-425.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARTX-425.

Explore the full profile